NO960863L - Fremgangsmåte for forlenget undertrykkelse av humoral immunitet - Google Patents

Fremgangsmåte for forlenget undertrykkelse av humoral immunitet

Info

Publication number
NO960863L
NO960863L NO960863A NO960863A NO960863L NO 960863 L NO960863 L NO 960863L NO 960863 A NO960863 A NO 960863A NO 960863 A NO960863 A NO 960863A NO 960863 L NO960863 L NO 960863L
Authority
NO
Norway
Prior art keywords
procedure
antagonist
humoral immunity
prolonged suppression
suppression
Prior art date
Application number
NO960863A
Other languages
English (en)
Other versions
NO321037B1 (no
NO960863D0 (no
Inventor
Randolph J Noelle
Teresa M Foy
Original Assignee
Dartmouth College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26813793&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO960863(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/232,929 external-priority patent/US5869049A/en
Application filed by Dartmouth College filed Critical Dartmouth College
Publication of NO960863D0 publication Critical patent/NO960863D0/no
Publication of NO960863L publication Critical patent/NO960863L/no
Publication of NO321037B1 publication Critical patent/NO321037B1/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
NO19960863A 1993-09-02 1996-03-01 Anvendelse av en gp39-antagonist og et TD antigen for fremstilling av et farmasoytisk preparat. NO321037B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11599093A 1993-09-02 1993-09-02
US08/232,929 US5869049A (en) 1993-09-02 1994-04-25 Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
PCT/US1994/009872 WO1995006480A1 (en) 1993-09-02 1994-09-02 Methods of prolonged suppression of humoral immunity

Publications (3)

Publication Number Publication Date
NO960863D0 NO960863D0 (no) 1996-03-01
NO960863L true NO960863L (no) 1996-04-30
NO321037B1 NO321037B1 (no) 2006-03-06

Family

ID=26813793

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19960863A NO321037B1 (no) 1993-09-02 1996-03-01 Anvendelse av en gp39-antagonist og et TD antigen for fremstilling av et farmasoytisk preparat.

Country Status (14)

Country Link
EP (1) EP0742721B1 (no)
JP (1) JP2840131B2 (no)
CN (1) CN1137726C (no)
AT (1) ATE179616T1 (no)
AU (3) AU7643094A (no)
DE (1) DE69418349T2 (no)
DK (1) DK0742721T3 (no)
ES (1) ES2134954T3 (no)
FI (1) FI106927B (no)
GR (1) GR3030762T3 (no)
IL (1) IL110852A (no)
NO (1) NO321037B1 (no)
NZ (1) NZ273208A (no)
WO (1) WO1995006480A1 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
ATE356634T1 (de) * 1997-01-10 2007-04-15 Biogen Idec Inc Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln
EP1101495A4 (en) * 1999-06-01 2003-05-07 Eisai Co Ltd PREVENTIVE AGENTS AGAINST IDIOPATHIC THROMOBOCYTOPENIC PURPURA
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
AU6158501A (en) 2000-05-12 2001-11-26 Beth Israel Hospital Compositions and methods for achieving immune suppression
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2013013708A1 (en) 2011-07-26 2013-01-31 Fundació Institut D'investigació Biomèdica De Bellvitge Treatment of acute rejection in renal transplant
EP3094652B1 (en) 2014-01-13 2021-09-29 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
US10669343B2 (en) 2015-08-05 2020-06-02 Janssen Biotech, Inc. Anti-CD154 antibodies and methods of using them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233051T2 (de) * 1991-10-25 2004-03-11 Immunex Corp., Seattle Antikörper gegen CD40-L
IL104684A0 (en) * 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
AU655349B2 (en) * 1992-02-17 1994-12-15 Kenji Nakamura An antibacterial porous inorganic capsule and a process for producing the same

Also Published As

Publication number Publication date
WO1995006480A1 (en) 1995-03-09
GR3030762T3 (en) 1999-11-30
FI960979A (fi) 1996-04-30
FI106927B (fi) 2001-05-15
IL110852A0 (en) 1994-11-28
DE69418349D1 (de) 1999-06-10
JPH09502184A (ja) 1997-03-04
AU2004240180B2 (en) 2007-08-09
ES2134954T3 (es) 1999-10-16
EP0742721A1 (en) 1996-11-20
DE69418349T2 (de) 1999-09-09
AU7643094A (en) 1995-03-22
AU2004240180A1 (en) 2005-01-27
FI960979A0 (fi) 1996-03-01
DK0742721T3 (da) 1999-11-01
NZ273208A (en) 2000-12-22
IL110852A (en) 1999-05-09
CN1137758A (zh) 1996-12-11
JP2840131B2 (ja) 1998-12-24
AU734853B2 (en) 2001-06-21
AU1422099A (en) 1999-04-01
EP0742721B1 (en) 1999-05-06
NO321037B1 (no) 2006-03-06
ATE179616T1 (de) 1999-05-15
NO960863D0 (no) 1996-03-01
CN1137726C (zh) 2004-02-11

Similar Documents

Publication Publication Date Title
NO960863L (no) Fremgangsmåte for forlenget undertrykkelse av humoral immunitet
GR3030568T3 (en) Inducing cytotoxic t lymphocyte responses.
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
DE122010000015I1 (de) Kombinierte Impfstoffe, die Hepatitis-B-Oberflächen antigen und andere Antigene enthalten
ATE326231T1 (de) Mutierendes enterotoxin als nichttoxisches orales adjuvans
CA2143823A1 (en) Retro-, inverso - and retro-inverso synthetic peptide analogues
Letscher-Bru et al. Protective effect of vaccination with a combination of recombinant surface antigen 1 and interleukin-12 against toxoplasmosis in mice
OA09880A (en) Induction of cytotoxic T-Lymphocyte Responses
ES2113882T3 (es) Vacuna oral que comprende un antigeno asociado superficialmente con eritrocitos.
EE9900343A (et) Sünteetiline polünukleotiid, immuunvastuste tekitamise meetod, immunogeenne kompositsioon, anti-HIV immuunvastuste indutseerimise meetod, meetod antigeeni tekitava raku indutseerimiseks ja farmatseutiline kompositsioon
AU6616301A (en) Modification of hepatitis b core antigen
EP0863913A4 (en) METHOD FOR RECOVERING THE DENSITY OF ANTIGENS ON ANTIGENT PRESENTING CELLS
EP0726758A4 (en) PEPTIDES FOR INDUCING A RESPONSE OF THE CYTOTOXIC T-LYMPHOCYTHES TARGETED AGAINST THE HEPATITIS B-VIRUS
DK0882132T3 (da) Et kombineret humant cytomegalovirus-antigen og anvendelse heraf
PT1021196E (pt) Utilizacao de uma solucao de clorito quimicamente estabilizada para inibir uma resposta imunitaria especifica para antigenio
WO1999011660A3 (en) Immunogenic polypeptides that mimic a surface polysaccharide antigen of a pathogenic microorganism, method for obtaining the same, and their use in vaccine compositions
OA08782A (en) Immunologically active polypeptides useful for the preparation of antimalarial vaccines and of diagnostic kits for the detection of antisporozoite antibodies.
IT8368342A0 (it) Procedimento e dispositivo per lapreparazione di bevande gassate particolarmente per uso in ambiente domestico
AU1796492A (en) Antigen recognized by antibodies associated with paraneoplastic opsoclonus and methods of use thereof
CA2128247A1 (en) Vaccines based on streptokinase
WO2001035993A3 (en) Compositions and methods for stimulating an immune response against infectious agents
DK0929315T3 (da) Krydsbeskyttende equine herpesviruspræparater, deres fremstilling og anvendelse
WO2003064612A3 (en) Identification of mutant antigens with enhanced immunogenicity
IT1256925B (it) Impiego di frammenti o/e di derivati della timosina alfa 1.
CA2246802A1 (en) A human cytomegalovirus combined antigen and its use

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees